Characteristics of study group
| Parameter . | Category . | CP (n = 1148) . | AP (n = 175) . | BP (n = 246) . |
|---|---|---|---|---|
| Age, y, n (%) | < 50 | 667 (58) | 118 (67) | 111 (45) |
| 50-60 | 273 (24) | 30 (17) | 62 (25) | |
| 61-70 | 160 (14) | 17 (10) | 59 (24) | |
| > 70 | 48 (4) | 10 (6) | 14 (6) | |
| Median (range) | 46 (4-86) | 42 (7-85) | 51 (16-81) | |
| Sex | Female | 454 (40) | 54 (31) | 97 (39) |
| Splenomegaly | Yes | 520/1142 (46) | 122/172 (71) | 86/191 (45) |
| Hemoglobin, g/dL | Median (range) | 11.9 (5-16.7) | 10.5 (5.1-16.3) | 9.7 (2-15.1) |
| WBC, × 109/L) | Median (range) | 78 (1.5-725) | 98.2 (0.6-813) | 37 (0-574) |
| Platelets, × 109/L) | Median (range) | 371 (21-3940) | 365 (22-1610) | 73 (2-2275) |
| Peripheral basophils, % | Median (range) | 3 (0-19) | 5 (0-43) | 1 (0.75) |
| Peripheral blasts, % | Median (range) | 1 (0-15) | 2 (0-29) | 35 (0-100) |
| Marrow basophils, % | Median (range) | 2 (0-19) | 5 (0-46) | 1 (0-44) |
| Marrow blasts, % | Median (range) | 1 (0-14) | 2 (0-26) | 46 (0-98) |
| Sokal risk, n (%) | Low | 549 (48) | ||
| Intermediate | 349 (30) | |||
| High | 228 (20) | |||
| NA | 22 (2) | |||
| Year of treatment, n (%) | < 1975 | 106 (9) | 21 (12) | 13 (5) |
| 1975-1982 | 110 (10) | 25 (14) | 29 (12) | |
| 1983-1990 | 165 (14) | 24 (14) | 41 (17) | |
| 1991-2000 | 352 (31) | 59 (34) | 80 (32) | |
| > 2000 | 415 (36) | 46 (26) | 83 (34) |
| Parameter . | Category . | CP (n = 1148) . | AP (n = 175) . | BP (n = 246) . |
|---|---|---|---|---|
| Age, y, n (%) | < 50 | 667 (58) | 118 (67) | 111 (45) |
| 50-60 | 273 (24) | 30 (17) | 62 (25) | |
| 61-70 | 160 (14) | 17 (10) | 59 (24) | |
| > 70 | 48 (4) | 10 (6) | 14 (6) | |
| Median (range) | 46 (4-86) | 42 (7-85) | 51 (16-81) | |
| Sex | Female | 454 (40) | 54 (31) | 97 (39) |
| Splenomegaly | Yes | 520/1142 (46) | 122/172 (71) | 86/191 (45) |
| Hemoglobin, g/dL | Median (range) | 11.9 (5-16.7) | 10.5 (5.1-16.3) | 9.7 (2-15.1) |
| WBC, × 109/L) | Median (range) | 78 (1.5-725) | 98.2 (0.6-813) | 37 (0-574) |
| Platelets, × 109/L) | Median (range) | 371 (21-3940) | 365 (22-1610) | 73 (2-2275) |
| Peripheral basophils, % | Median (range) | 3 (0-19) | 5 (0-43) | 1 (0.75) |
| Peripheral blasts, % | Median (range) | 1 (0-15) | 2 (0-29) | 35 (0-100) |
| Marrow basophils, % | Median (range) | 2 (0-19) | 5 (0-46) | 1 (0-44) |
| Marrow blasts, % | Median (range) | 1 (0-14) | 2 (0-26) | 46 (0-98) |
| Sokal risk, n (%) | Low | 549 (48) | ||
| Intermediate | 349 (30) | |||
| High | 228 (20) | |||
| NA | 22 (2) | |||
| Year of treatment, n (%) | < 1975 | 106 (9) | 21 (12) | 13 (5) |
| 1975-1982 | 110 (10) | 25 (14) | 29 (12) | |
| 1983-1990 | 165 (14) | 24 (14) | 41 (17) | |
| 1991-2000 | 352 (31) | 59 (34) | 80 (32) | |
| > 2000 | 415 (36) | 46 (26) | 83 (34) |